January 2007- Volume 3, Issue 1

January 2007

In this Issue

Genomics & Proteomics

Intrexon buys majority stake in RheoGene

Intrexon buys majority stake in RheoGene

Merger creates a biotech firm targeting gene-based therapies

Q&A: Troy Moore, CTO, Open Biosystems

Q&A: Troy Moore, CTO, Open Biosystems

Inspired by the open source software movement and the open sharing of knowledge and discoveries that occurred during the Human Genome Project, Brian Pollock and Troy Moore founded Huntsville, Ala.-based Open Biosystems in 2001

Genetics tailored to fit

Genetics tailored to fit

Invitrogen to become exclusive worldwide distributor of Blue Heron\'s custom gene services

Partnering up for sample prep

Partnering up for sample prep

Pressure BioSciences enters three-month \"proof-of-concept\" collaboration with Alfa Wassermann

Q&A: Troy Moore, CTO Open Biosystems

Q&A: Troy Moore, CTO Open Biosystems

Inspired by the open source software movement and the open sharing of knowledge and discoveries that occurred during the Human Genome Project, Brian Pollock and Troy Moore founded Huntsville, Ala.-based Open Biosystems in 2001

Research & Development

A validating HCV deal

A validating HCV deal

Enanta pockets $57 million upfront in protease inhibitor deal with Abbott

Paying the toll for vaccines

Paying the toll for vaccines

Idera strikes multimillion-dollar deal for use of Toll-like Receptor agonists in Merck vaccines.

Heart-felt matchup

Heart-felt matchup

Cytokinetics and Amgen to research and market cardiac contractility drugs

Enanta pockets $57 million in HCV deal with Abbott

Enanta pockets $57 million in HCV deal with Abbott

WATERTOWN, Mass.—Enanta Pharmaceuticals and Abbott announced in early December a worldwide agreement for the research, development and commercialization of hepatitis C virus (HCV) NS3 and NS3/4A protease inhibitors.

Automation & Instrumentation

Automating Digital Pathology

Automating Digital Pathology

DMetrix, Definiens to provide high-throughput image capture and automated analysis

One for the tools: PerkinElmer acquires Evotec

One for the tools: PerkinElmer acquires Evotec

Looking to fill in its line of equipment focused on cell-based assays, Perkin Elmer Inc. announced late last year the acquisition of Evotec AG’s subsidiary Evotec Technologies.

Two for the cells: PerkinElmer buys Euroscreen

Two for the cells: PerkinElmer buys Euroscreen

Following close on the heels of the announcement that it had acquired new instrumentation and software lines through its buyout of Evotec Technologeis, PerkinElmer announced in late December its intent to also acquire Euroscreen Products S.A.

A license to amplify

A license to amplify

Sigma-aldrich secures whole transcriptome amplification technology from Rubicon Genomics

Pocket change: Thermo Fisher buys Cohesive for $25 million

Pocket change: Thermo Fisher buys Cohesive for $25 million

Thermo Fisher Scientific Inc. announced the acquisition of Massachusetts-based Cohesive Technologies Inc., a manufacturer of advanced TLX turbulent flow sample extraction and liquid chromatography products.

DMetrix, Definiens to provide high-throughput image capture, automated analysis

DMetrix, Definiens to provide high-throughput image capture, automated analysis

TUCSON, Ariz.—DMetrix Inc., the developer of ultra-rapid, array-microscope digital imaging systems, announced that it has formed a partnership with Definiens AG, based in Munich, Germany. Their goal is to accelerate the development of a system that will provide completely automated digital pathology.

DMetrix, Definiens to provide high-throughput image capture, analysis

DMetrix, Definiens to provide high-throughput image capture, analysis

DMetrix Inc., the developer of ultra-rapid, array-microscope digital imaging systems, announced that it has formed a partnership with Definiens AG, based in Munich, Germany. Their goal is to accelerate the development of a system that will provide completely automated digital pathology

Informatics

Getting to the core of the matter

Getting to the core of the matter

Almac licenses MetaCore for cancer-oriented microarrays and genomic services

Getting under your skin

Getting under your skin

New Entelos platform gives in silico peek at dermatological efficacy and events

Legitimizing license

Legitimizing license

Health Discovery Corp. grants SVM patent license to Pfizer

Q&A: Neil Kipling, fouder and CEO IDBS

Q&A: Neil Kipling, fouder and CEO IDBS

Guiildford, U.K.-based software developer IDBS is probably best known in the industry for its suite of drug discovery software products called ActivityBase.

Max Planck expands access to Elsevier portfolio

Max Planck expands access to Elsevier portfolio

MUNICH, Germany—Having operated on a decentralized basis with their library information services until now, the Max Planck Society recently entered into an agreement with Amsterdam-based scientific publisher Elsevier.

Almac licenses MetaCore for cancer-oriented microarrays and genomic services

Almac licenses MetaCore for cancer-oriented microarrays and genomic services

CRAIGAVON, Northern Ireland—Almac Group announced recently a decision to license St. Joseph, Mich.-based GeneGo’s flagship data mining suite, MetaCore, for use by its Almac Diagnostics division.
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022